These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 38957786)

  • 41. Route of 41BB/41BBL Costimulation Determines Effector Function of B7-H3-CAR.CD28ζ T Cells.
    Nguyen P; Okeke E; Clay M; Haydar D; Justice J; O'Reilly C; Pruett-Miller S; Papizan J; Moore J; Zhou S; Throm R; Krenciute G; Gottschalk S; DeRenzo C
    Mol Ther Oncolytics; 2020 Sep; 18():202-214. PubMed ID: 32728609
    [TBL] [Abstract][Full Text] [Related]  

  • 42. New Emerging Targets in Cancer Immunotherapy: The Role of B7-H3.
    Koumprentziotis IA; Theocharopoulos C; Foteinou D; Angeli E; Anastasopoulou A; Gogas H; Ziogas DC
    Vaccines (Basel); 2024 Jan; 12(1):. PubMed ID: 38250867
    [TBL] [Abstract][Full Text] [Related]  

  • 43. B7-H3 as a Target for CAR-T Cell Therapy in Skull Base Chordoma.
    Long C; Li G; Zhang C; Jiang T; Li Y; Duan X; Zhong G
    Front Oncol; 2021; 11():659662. PubMed ID: 34868903
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Remodeling of Tumor Microenvironment by Tumor-Targeting Nanozymes Enhances Immune Activation of CAR T Cells for Combination Therapy.
    Zhu L; Liu J; Zhou G; Liu TM; Dai Y; Nie G; Zhao Q
    Small; 2021 Oct; 17(43):e2102624. PubMed ID: 34378338
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A drug screening to identify novel combinatorial strategies for boosting cancer immunotherapy efficacy.
    Zhang Z; Wang G; Zhong K; Chen Y; Yang N; Lu Q; Yuan B; Wang Z; Li H; Guo L; Zhang R; Wu Z; Zheng M; Zhao S; Tang X; Shao B; Tong A
    J Transl Med; 2023 Jan; 21(1):23. PubMed ID: 36635683
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hopes on immunotherapy targeting B7-H3 in neuroblastoma.
    Pulido R; Nunes-Xavier CE
    Transl Oncol; 2023 Jan; 27():101580. PubMed ID: 36327699
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Advances in immunotherapeutic targets for childhood cancers: A focus on glypican-2 and B7-H3.
    Li N; Spetz MR; Li D; Ho M
    Pharmacol Ther; 2021 Jul; 223():107892. PubMed ID: 33992682
    [TBL] [Abstract][Full Text] [Related]  

  • 48. B7-H3 Chimeric Antigen Receptor Redirected T Cells Target Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma.
    Zi Z; Zhao H; Wang H; Ma X; Wei F
    Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33348781
    [TBL] [Abstract][Full Text] [Related]  

  • 49. B7-H3-targeted CAR T cell activity is enhanced by radiotherapy in solid cancers.
    Ventin M; Cattaneo G; Maggs L; Jia J; Arya S; Ferrone S; Wang X; Ferrone CR
    Front Oncol; 2023; 13():1193963. PubMed ID: 37483496
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Targeting Radiation-Resistant Prostate Cancer Stem Cells by B7-H3 CAR T Cells.
    Zhang Y; He L; Sadagopan A; Ma T; Dotti G; Wang Y; Zheng H; Gao X; Wang D; DeLeo AB; Fan S; Sun R; Yu L; Zhang L; Wang G; Ferrone S; Wang X
    Mol Cancer Ther; 2021 Mar; 20(3):577-588. PubMed ID: 33653946
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors: The Past and the Future.
    Srour SA; Akin S
    J Immunother Precis Oncol; 2023 Feb; 6(1):19-30. PubMed ID: 36751657
    [TBL] [Abstract][Full Text] [Related]  

  • 52. B7-H3 and its role in bone cancers.
    He L; Li Z
    Pathol Res Pract; 2019 Jun; 215(6):152420. PubMed ID: 31060912
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
    Pearson AD; Rossig C; Mackall C; Shah NN; Baruchel A; Reaman G; Ricafort R; Heenen D; Bassan A; Berntgen M; Bird N; Bleickardt E; Bouchkouj N; Bross P; Brownstein C; Cohen SB; de Rojas T; Ehrlich L; Fox E; Gottschalk S; Hanssens L; Hawkins DS; Horak ID; Taylor DH; Johnson C; Karres D; Ligas F; Ludwinski D; Mamonkin M; Marshall L; Masouleh BK; Matloub Y; Maude S; McDonough J; Minard-Colin V; Norga K; Nysom K; Pappo A; Pearce L; Pieters R; Pule M; Quintás-Cardama A; Richardson N; Schüßler-Lenz M; Scobie N; Sersch MA; Smith MA; Sterba J; Tasian SK; Weigel B; Weiner SL; Zwaan CM; Lesa G; Vassal G
    Eur J Cancer; 2022 Jan; 160():112-133. PubMed ID: 34840026
    [TBL] [Abstract][Full Text] [Related]  

  • 54. CAR-T Therapy for Pediatric High-Grade Gliomas: Peculiarities, Current Investigations and Future Strategies.
    Antonucci L; Canciani G; Mastronuzzi A; Carai A; Del Baldo G; Del Bufalo F
    Front Immunol; 2022; 13():867154. PubMed ID: 35603195
    [TBL] [Abstract][Full Text] [Related]  

  • 55. MEK Inhibitor Augments Antitumor Activity of B7-H3-Redirected Bispecific Antibody.
    Li H; Huang C; Zhang Z; Feng Y; Wang Z; Tang X; Zhong K; Hu Y; Guo G; Zhou L; Guo W; Xu J; Yang H; Tong A
    Front Oncol; 2020; 10():1527. PubMed ID: 32984002
    [TBL] [Abstract][Full Text] [Related]  

  • 56. B7-H3-Targeted CAR-Vδ1T Cells Exhibit Potent Broad-Spectrum Activity Against Solid Tumors.
    Jiang L; You F; Wu H; Qi C; Xiang S; Zhang P; Meng H; Wang M; Huang J; Li Y; Chen D; An G; Yang N; Zhang B; Shen L; Yang L
    Cancer Res; 2024 Sep; ():. PubMed ID: 39240694
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Highly proliferative and hypodifferentiated CAR-T cells targeting B7-H3 enhance antitumor activity against ovarian and triple-negative breast cancers.
    Zhang X; Guo H; Chen J; Xu C; Wang L; Ke Y; Gao Y; Zhang B; Zhu J
    Cancer Lett; 2023 Sep; 572():216355. PubMed ID: 37597651
    [TBL] [Abstract][Full Text] [Related]  

  • 58. B7-H3 as a Novel CAR-T Therapeutic Target for Glioblastoma.
    Tang X; Zhao S; Zhang Y; Wang Y; Zhang Z; Yang M; Zhu Y; Zhang G; Guo G; Tong A; Zhou L
    Mol Ther Oncolytics; 2019 Sep; 14():279-287. PubMed ID: 31485480
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Challenges and Prospects of Chimeric Antigen Receptor T-cell Therapy for Metastatic Prostate Cancer.
    Gorchakov AA; Kulemzin SV; Kochneva GV; Taranin AV
    Eur Urol; 2020 Mar; 77(3):299-308. PubMed ID: 31471138
    [TBL] [Abstract][Full Text] [Related]  

  • 60. CAR-T Therapies in Solid Tumors: Opportunities and Challenges.
    Guzman G; Reed MR; Bielamowicz K; Koss B; Rodriguez A
    Curr Oncol Rep; 2023 May; 25(5):479-489. PubMed ID: 36853475
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.